COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS
申请人:Massachusetts General Hospital
公开号:US20140296232A1
公开(公告)日:2014-10-02
The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:
本发明涉及式I的化合物或其药学上可接受的盐、酯或前药:
Compounds for the treatment of mycobacterial infections
申请人:The Broad Institute, Inc.
公开号:US10766872B2
公开(公告)日:2020-09-08
The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:
本发明涉及式 I 化合物或其药学上可接受的盐、酯或原药:
Synthesis and structure–activity relationships of phenyl-substituted coumarins with anti-tubercular activity that target FadD32
作者:Tomohiko Kawate、Noriaki Iwase、Motohisa Shimizu、Sarah A. Stanley、Samantha Wellington、Edward Kazyanskaya、Deborah T. Hung
DOI:10.1016/j.bmcl.2013.09.035
日期:2013.11
In an effort to develop new and potent agents for therapy against tuberculosis, a high-throughput screen was performed against Mycobacterium tuberculosis strain H37Rv. Two 6-aryl-5,7-dimethyl-4-phenylcoumarin compounds 1a and 1b were found with modest activity. A series of coumarin derivatives were synthesized to improve potency and to investigate the structure-activity relationship of the series. Among them, compounds 1o and 2d showed improved activity with IC90 of 2 mu M and 0.5 mu M, respectively. Further optimization provided compound 3b with better physiochemical properties with IC90 0.4 mu M which had activity in a mouse model of infection. The role of the conformation of the 4- and 6-aryl substituents is also described. (c) 2013 Elsevier Ltd. All rights reserved.